02004nas a2200361   4500000000100000008004100001260001300042653001200055653002300067653002600090653002100116653004300137653002200180653003100202653003000233653001600263653001100279653002300290653002900313653001200342653001000354653002900364653002900393653001300422653001700435653002800452100001600480245001400496300000900510490000700519520110200526022001401628       1976                            d  c1976 Jul10aAnimals10aAntibody Formation10aAntineoplastic Agents10aAntiviral Agents10aChemical and Drug Induced Liver Injury10aDrug Interactions10aDrug Resistance, Microbial10aDrug Therapy, Combination10aForecasting10aHumans10aImmunity, Cellular10aImmunosuppressive Agents10aleprosy10aLiver10aMeningococcal Infections10aMycobacterium Infections10aRifampin10aTuberculosis10aTuberculosis, Pulmonary1 aSanders W E00aRifampin.  a82-60 v853 a<p>In 1971, rifampin was approved for treatment of pulmonary tuberculosis and asymptomatic carriers of Neisseria meningitidis. At present, the approved indications remain the same. However, rifampin in conjunction with at least one other antituberculous drug may be of great value in therapy of extrapulmonary tuberculosis and infections due to other susceptible mycobacteria. In addition, results of clinical trials in leprosy have been highly encouraging. Rifampin appears to induce light chain proteinuria in a majority of patients and has been implicated in suppression of both humoral and cell-mediated immune responses. However, these effects appear to have been of little consequence to treated patients. A variety of possibly immunologically mediated reactions to rifampin has been closely associated with irregular administration of the drug. These reactions and hepatic toxcity may be preventable in many patients. Rifampin or one of its congeners, alone or in combination with other antibiotics, may prove useful in treatment of various infectious, and possibly malignant, diseases.</p>  a0003-4819